Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies
Abstract Endocrine therapy (ET) is recommended as first-line therapy for the majority of patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative advanced breast cancer (ABC); however, the efficacy of ET in patients with visceral metastases (VM) versus patients whose d...
Main Authors: | John F. R. Robertson, Angelo Di Leo, Stephen Johnston, Stephen Chia, Judith M. Bliss, Robert J. Paridaens, Jasmine Lichfield, Ian Bradbury, Christine Campbell |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-02-01
|
Series: | npj Breast Cancer |
Online Access: | https://doi.org/10.1038/s41523-021-00222-y |
Similar Items
-
Nab-paclitaxel monotherapy in patients with metastatic breast cancer with visceral crisis: evaluation of efficacy and tolerability in clinical practice
by: L. Yu. Vladimirova, et al.
Published: (2019-06-01) -
Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients.
by: Gu-Shun Lai, et al.
Published: (2024-01-01) -
Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis
by: Mirosława Püsküllüoğlu, et al.
Published: (2024-06-01) -
Survival Patterns Based on First-site–specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?
by: Mohamed E. Ahmed, et al.
Published: (2024-08-01) -
Metastatic melanoma with sebocyte-like melanocytes and widespread visceral involvement
by: Li-Wei Chang, et al.
Published: (2020-04-01)